This document discusses personalized cancer vaccines created using neoantigens unique to a patient's tumor. The process involves procuring tumor cells from the patient for genetic sequencing to identify neoantigens. Predicted mutated peptides likely to bind the patient's HLA proteins are then synthesized into a personalized vaccine administered to the patient to trigger an immune response against tumors containing the same neoantigens. The company discussed offers DNA/RNA sequencing, neoantigen prediction and personalized vaccine manufacturing services.